UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 10, 2023

IRADIMED CORPORATION
(Exact Name of Registrant as Specified in Its Charter)

001-36534
(Commission File Number)

Delaware
73-1408526
(State or Other Jurisdiction of Incorporation)
(I.R.S. Employer Identification No.)

1025 Willa Springs Dr., 
Winter Springs, FL 32708
(Address of principal executive offices, including zip code)

(407) 677-8022
(Registrant’s telephone number, including area code)

NOT APPLICABLE
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common stock, par value $0.0001
IRMD
NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Securities registered pursuant to Section 12(b) of the Act:

Title of each class:
  
Trading Symbol
  
Name of each exchange on which registered:
Common stock, par value $0.0001
  
IRMD
  
NASDAQ Capital Market






Item 8.01    Other Events.

On May 10, 2023, Iradimed Corporation issued a press release announcing that it was recently named on Forbes’ latest list of America’s Best Small Companies for 2023.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. and is incorporated herein by reference. The information contained herein, including the exhibit furnished herewith, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.
Description
104
Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 10, 2023 IRADIMED CORPORATION  
       

By:
/s/ John Glenn  
  Name:
 John Glenn  
  Title:
 Chief Financial Officer  
       

:

EXHIBIT 99.1



IRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes
Winter Springs, Florida, May 10, 2023 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), was recently named on Forbes’ latest list of America’s Best Small Companies for 2023. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
To find the 100 best performers, Forbes used data from FactSet to compile its annual list of America’s Best Small Companies. Forbes screened more than 1,000 companies with a market value between $300 million and $2 billion to find 541 companies that had both positive sales growth over the past 12 months and a share price of at least $5. Financial institutions, REITs, utilities, royalty trusts, and limited partnerships were excluded, as were companies that have been public for less than one year. The ranking is based on earnings growth, sales growth, return on equity, and total stock return for the latest 12 months available and over the last five years. 
"I am incredibly honored and proud that Iradimed has been named one of America’s Top 100 Small Companies by Forbes,” said Roger Susi, President and Chief Executive Officer of the Company. “This recognition is a testament to the hard work and dedication of our entire team, and we are grateful for the support of our customers and shareholders. We remain committed to delivering unique patient safety devices to our customers, exceptional value to our shareholders, and driving sustained growth for our business."
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We develop, manufacture, market, and distribute MRI-compatible medical devices and accessories, disposables, and services relating to them.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually
anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
For more information please visit www.iradimed.com.
Media Contact:
IRADIMED CORPORATION
(407) 677‑8022
[email protected]